NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical & Scientific Conference
NeuBase Therapeutics announced an oral presentation at the 2021 Muscular Dystrophy Association Conference on March 18, 2021. The presentation, titled Resolution of Causality in Myotonic Dystrophy, Type 1 (DM1) via a PATrOL™-Enabled Therapy, will showcase preclinical data on their innovative PATrOL™ therapy for DM1 treatment. The presentation will be delivered by Dietrich A. Stephan, Ph.D., CEO of NeuBase, from 9:30 a.m. to 9:45 a.m. EDT. NeuBase focuses on genetic therapies aimed at addressing genetic defects using synthetic medicines. For more, visit neubasetherapeutics.com.
- None.
- None.
PITTSBURGH, March 16, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today an oral presentation at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference being held from March 15-18, 2021. The presentation, entitled Resolution of Causality in Myotonic Dystrophy, Type 1 (DM1) via a PATrOL™-Enabled Therapy, will provide an overview of NeuBase’s positive in vitro and in vivo preclinical data for its PATrOL™-enabled therapy for the treatment of myotonic dystrophy type 1 (DM1).
Presentation Details
Title: Resolution of Causality in Myotonic Dystrophy, Type 1 (DM1) via a PATrOL™-Enabled Therapy
Presenter: Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase
Date: March 18, 2021
Time: 9:30 a.m.-9:45 a.m. EDT
For more information and to register for the conference, visit: https://mdaconference.org/.
About NeuBase Therapeutics, Inc.
NeuBase is accelerating the genetic revolution using a new class of synthetic medicines which have been shown to be able to increase, decrease and change gene function, as appropriate, to resolve causal genetic defects in living systems. NeuBase's designer PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.
Use of Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements are distinguished by use of words such as "will," "would," "anticipate," "expect," "believe," "designed," "plan," or "intend," the negative of these terms, and similar references to future periods. These views involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements. Our forward-looking statements contained herein speak only as of the date of this press release. Factors or events that we cannot predict, including those risk factors contained in our filings with the U.S. Securities and Exchange Commission, may cause our actual results to differ from those expressed in forward-looking statements. The Company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on the Company's current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this press release, including: the Company's plans to develop and commercialize its product candidates; the timing of initiation of the Company's planned clinical trials; the timing of the availability of data from the Company's clinical trials; the timing of any planned investigational new drug application or new drug application; the Company's plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of the Company's product candidates; the Company's commercialization, marketing and manufacturing capabilities and strategy; global health conditions, including the impact of COVID-19; the Company's ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all, as well as those risk factors contained in our filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.
NeuBase Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
OP: (617) 535-7746
NeuBase Media Contact:
Cait Williamson, Ph.D.
LifeSci Communications
cait@lifescicomms.com
OP: (646) 751-4366
FAQ
What is the focus of NeuBase Therapeutics' presentation at the MDA Conference?
When will NeuBase present their findings at the MDA Conference?
Who will present at the NeuBase session during the MDA Conference?
What are the main topics discussed in the NeuBase presentation?
Where can I find more information about NeuBase Therapeutics?
